JP2016523955A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523955A5
JP2016523955A5 JP2016524931A JP2016524931A JP2016523955A5 JP 2016523955 A5 JP2016523955 A5 JP 2016523955A5 JP 2016524931 A JP2016524931 A JP 2016524931A JP 2016524931 A JP2016524931 A JP 2016524931A JP 2016523955 A5 JP2016523955 A5 JP 2016523955A5
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523955A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/062983 external-priority patent/WO2015004618A1/en
Publication of JP2016523955A publication Critical patent/JP2016523955A/ja
Publication of JP2016523955A5 publication Critical patent/JP2016523955A5/ja
Pending legal-status Critical Current

Links

JP2016524931A 2013-07-10 2014-07-09 Zesteホモログ2エンハンサー阻害剤 Pending JP2016523955A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844540P 2013-07-10 2013-07-10
US61/844,540 2013-07-10
PCT/IB2014/062983 WO2015004618A1 (en) 2013-07-10 2014-07-09 Enhancer of zeste homolog 2 inhibitors

Publications (2)

Publication Number Publication Date
JP2016523955A JP2016523955A (ja) 2016-08-12
JP2016523955A5 true JP2016523955A5 (US07846941-20101207-C00217.png) 2017-08-24

Family

ID=51212901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524931A Pending JP2016523955A (ja) 2013-07-10 2014-07-09 Zesteホモログ2エンハンサー阻害剤

Country Status (10)

Country Link
US (1) US9556157B2 (US07846941-20101207-C00217.png)
EP (1) EP3019494B1 (US07846941-20101207-C00217.png)
JP (1) JP2016523955A (US07846941-20101207-C00217.png)
KR (1) KR20160030221A (US07846941-20101207-C00217.png)
CN (1) CN105473580A (US07846941-20101207-C00217.png)
AU (1) AU2014288839B2 (US07846941-20101207-C00217.png)
CA (1) CA2917463A1 (US07846941-20101207-C00217.png)
ES (1) ES2640386T3 (US07846941-20101207-C00217.png)
RU (1) RU2016104044A (US07846941-20101207-C00217.png)
WO (1) WO2015004618A1 (US07846941-20101207-C00217.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013361079B2 (en) * 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
JP6571180B2 (ja) * 2014-10-28 2019-09-04 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Zesteホモログ2エンハンサー阻害剤
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
UY36758A (es) * 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017079757A1 (en) * 2015-11-06 2017-05-11 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
JP7203018B2 (ja) 2016-09-26 2023-01-12 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド クロモボックスタンパク質阻害剤およびその使用
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CA3089639C (en) 2018-01-31 2024-06-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6924376B2 (en) 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP5864546B2 (ja) 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インダゾール
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
ES2627085T3 (es) 2010-05-07 2017-07-26 Glaxosmithkline Llc Indoles
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
RU2014117632A (ru) 2011-09-30 2015-11-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способы лечения злокачественной опухоли
WO2013075084A1 (en) * 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013216721B2 (en) 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
RU2699546C2 (ru) 2012-04-13 2019-09-06 Эпизайм, Инк. Комбинированная терапия для лечения рака
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CN110041250A (zh) 2012-10-15 2019-07-23 Epizyme股份有限公司 经取代的苯化合物
JP2016503009A (ja) 2012-12-13 2016-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC Zesteホモログ2エンハンサー阻害剤
AU2013361079B2 (en) * 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
AU2014261075B2 (en) 2013-04-30 2017-01-19 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds

Similar Documents

Publication Publication Date Title
JP2016523955A5 (US07846941-20101207-C00217.png)
JP2015537020A5 (US07846941-20101207-C00217.png)
JP2013545785A5 (US07846941-20101207-C00217.png)
CY1123545T1 (el) Ν-σουλφονυλιωμενα πυραζολο[3,4-β]πυριδιν-6-καρβοξαμιδια και μεθοδος χρησης
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2014503525A5 (US07846941-20101207-C00217.png)
WO2016134301A3 (en) Neuroactive steroids, compositions, and uses thereof
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
JP2014051526A5 (US07846941-20101207-C00217.png)
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
JP2015504081A5 (US07846941-20101207-C00217.png)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
JP2016515561A5 (US07846941-20101207-C00217.png)
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
JP2016503793A5 (US07846941-20101207-C00217.png)
JP2014506907A5 (US07846941-20101207-C00217.png)
JP2014511892A5 (US07846941-20101207-C00217.png)
AU2018253590A1 (en) Imidazopyridazine compounds
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
JP2019516739A5 (US07846941-20101207-C00217.png)
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
TW201613864A (en) Novel compounds